EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Quercetin and Its Structural Analogs as NUDT5 Inhibitors: A Preliminary In Silico Study

Emilia Gligorić iD, Milica Vidić iD, Branislava Teofilović iD, Nevena Grujić-Letić iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26188843 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Emilia Gligorić und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Faculty of Medicine, University of Novi Sad, Hajduk Veljkova 3, 21000 Novi Sad, Serbia. Hauptthemen laut MEDLINE: Quercetin, Pyrophosphatases, Enzyme Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hungarian Academy of Sciences, MTA Domus Hungarica Scientiarium et Artium program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nucleotide diphosphate hydrolase type 5 (NUDT5) plays a significant role in the estrogen-signaling pathway and is overexpressed in breast cancer. This study aimed to explore the anti-breast cancer potential of quercetin and its 52 structural analogs by targeting the NUDT5 enzyme using the in silico molecular docking method. Moreover, Molecular Mechanics/General Born Surface Area (MM/GBSA) calculations were performed for compounds with superior binding affinity scores than quercetin. Their drug-likeness, according to Lipinski’s rule of five, water solubility, and Caco-2 permeability were predicted. In addition, the absorption, distribution, metabolism, excretion, and toxicity (ADMET) profile was determined for the top-scoring compounds from the docking studies and MM/GBSA calculations, as well as for those that complied with the rules of Lipinski and exhibited high permeability. The obtained results showed that all the tested ligands interact with the active site of NUDT5. Their binding energies ranged from −11.24 to −7.36 kcal/mol. The MM/GBSA calculations further supported the binding affinity predictions. ADMET analysis enabled the selection of compounds with favorable pharmacokinetic profiles in comparison to quercetin. Quercetin analogs L1 and L28 were identified as promising anti-breast cancer drug candidates worthy of further experimental evaluation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

QuercetinPyrophosphatasesEnzyme InhibitorsHumansMolecular Docking SimulationCaco-2 CellsComputer SimulationBreast NeoplasmsProtein BindingNudix Hydrolases

Stichwörter der Autor:innen

ADMETNUDT5molecular dockingquercetinstructural analog

Substanzen

QuercetinPyrophosphatasesEnzyme InhibitorsNUDT15 protein, humanNudix Hydrolases

Autor:innen und Institutionen

  • Department of Pharmacy, Faculty of Medicine, University of Novi Sad, Hajduk Veljkova 3, 21000 Novi Sad, Serbia.

ORCID-Profile: Emilia Gligorić, Milica Vidić, Branislava Teofilović, Nevena Grujić-Letić

Förderung

  • Hungarian Academy of Sciences
  • MTA Domus Hungarica Scientiarium et Artium program

Zitieren

APA

Gligorić, E., Vidić, M., Teofilović, B., & Grujić-Letić, N. (2025). Quercetin and Its Structural Analogs as NUDT5 Inhibitors: A Preliminary In Silico Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26188843

Vancouver

Gligorić E, Vidić M, Teofilović B, Grujić-Letić N. Quercetin and Its Structural Analogs as NUDT5 Inhibitors: A Preliminary In Silico Study. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26188843

BibTeX
@article{Gligori2025,
  author = {Gligorić, Emilia and Vidić, Milica and Teofilović, Branislava and Grujić-Letić, Nevena},
  title = {Quercetin and Its Structural Analogs as NUDT5 Inhibitors: A Preliminary In Silico Study},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26188843}
}
Kostenlos starten →